SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both ...

The AAD/NPF guidelines define mild psoriasis as <3% BSA and moderate ... often come into play when deciding how to start psoriasis treatment. "I usually start with topical steroids," he said.

You may be able to manage mild psoriasis on your feet with home remedies such as moisturizers and over-the-counter treatments like hydrocortisone 1% cream. However, more severe psoriasis may ...

Under the NPF classification, psoriasis is considered mild when lesions cover less than 2% of the body surface area (typically on the knees, elbows, scalp, hands, and feet). Topical treatments ...

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

"Our tailored approach to immune regulation holds promise in providing a safer, more efficacious oral treatment for patients suffering from psoriasis." "Mild-to-moderate patients represent over 80 ...

All treatment emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) and were mild or moderate. Psoriasis is a chronic, recurrent, inflammatory, and immune-mediated systemic ...